Literature DB >> 34252800

Early phago-/endosomal escape of platinum drugs via ROS-responsive micelles for dual cancer chemo/immunotherapy.

Pei-Wei Shueng1, Lu-Yi Yu2, Hsin-Cheng Chiu3, Hui-Ching Chang2, Yen-Ling Chiu4, Tzu-Yu Kuo2, Yu-Wei Yen2, Chun-Liang Lo5.   

Abstract

Recent studies have indicated that cancer treatment based on immunotherapy alone is not viable. Combined treatment with other strategies is required to achieve the expected therapeutic effect. Reactive oxygen species (ROS) play an important role in regulating cancer cells and the tumor microenvironment, even in immune cells. However, rigorous regulation of the ROS level within the entire tumor tissue is difficult, limiting the application of ROS in cancer therapy. Therefore, we design an early phago-/endosome-escaping micelle that can release platinum-based drugs into the cytoplasm of macrophages and cancer cells, thereby enhancing the ROS levels of the entire tumor tissue; inducing apoptosis of cancer cells, down-regulation of CD47 expression of cancer cells, polarization of M1 macrophages, and phagocytosis of cancer cells by M1 macrophages; and achieving the dual effect of chemotherapy and macrophage-mediated immunotherapy.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Immunotherapy; Phago-/endosomal escape; Polymeric micelles; Tumor-associated macrophages

Year:  2021        PMID: 34252800     DOI: 10.1016/j.biomaterials.2021.121012

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  2 in total

Review 1.  Oxidative Stress in Cancer Immunotherapy: Molecular Mechanisms and Potential Applications.

Authors:  Ruolan Liu; Liyuan Peng; Li Zhou; Zhao Huang; Chengwei Zhou; Canhua Huang
Journal:  Antioxidants (Basel)       Date:  2022-04-27

2.  BSA-MnO2-SAL multifunctional nanoparticle-mediated M1 macrophages polarization for glioblastoma therapy.

Authors:  Fuming Liang; Ling Zhu; Chen Wang; Yanlian Yang; Zhaohui He
Journal:  RSC Adv       Date:  2021-11-02       Impact factor: 3.361

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.